Organoid Core

About Our Organoid Core Facility

Every patient's tumor is unique for the genetic and epigenetic changes they possess. Traditional cancer-derived cell lines have been the work-horse of discovery and preclinical studies. However, the long-term culture induces significant divergence from the tumor they were generated from and hence does not always represent the primary cancers observed in patients. The discordance between cell line models and patient tumors is frequently cited as an important factor contributing to results that fail to translate to the clinic. Recent advances in our ability to grow a patients' tumor in culture as three-dimensional tumor organoids (mini-tumors)open new options for using patient tumor-derived cells for translational or clinical research and offers an opportunity to shorten the distance between the bench and the bedside.

Recent studies from our laboratory have demonstrated that tumor organoids in culture effectively model in vivo drug-response and are effective for discovering clinically actionable secreted and glycosylation biomarkers. Thus, we believe the tumor organoid technology offers an experimental platform closer to the patients' tumors with high in vivo and clinical relevance.


  • A panel of tumor organoids models generated directly from patient tumors or patient tumor-derived xenograft.
  • Training and know-how for culturing and using organoid cultures for preclinical and discovery research.
  • Frozen media cocktails.
  • Access to drug printer for drug-sensitivity research


Organoid line as a cryopreserved vial or active culture: $1000
Media cocktail (frozen aliquot with instructions for resuspension): $500/500 ml
Drug printer: $100 for each cartridge and use of the printer


Senthil K Muthuswamy, PhD


Dipikaa Akshinthala, MS
Manager of Operations and Training